The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development
暂无分享,去创建一个
Marco Siccardi | Nicolas Cottura | Alice Howarth | Rajith K.R. Rajoli | M. Siccardi | R. Rajoli | N. Cottura | A. Howarth | Nicolas Cottura
[1] D. Bouard,et al. Viral vectors: from virology to transgene expression , 2009, British journal of pharmacology.
[2] Jim E Riviere,et al. A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice , 2015, Nanotoxicology.
[3] G. Calin,et al. Progresses towards safe and efficient gene therapy vectors , 2015, Oncotarget.
[4] T. Ishida,et al. Liposomal Delivery Systems: Design Optimization and Current Applications. , 2017, Biological & pharmaceutical bulletin.
[5] P. Møller,et al. Nanodelivery systems and stabilized solid-drug nanoparticles for orally administered medicine: current landscape , 2018, International journal of nanomedicine.
[6] S. Mitragotri,et al. Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.
[7] Ninad Varkhede,et al. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model. , 2018, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[8] P. Annaert,et al. Modeling the Time Course of the Tissue Responses to Intramuscular Long-acting Paliperidone Palmitate Nano-/Microcrystals and Polystyrene Microspheres in the Rat , 2016, Toxicologic pathology.
[9] Samir Mitragotri,et al. Nanoparticles in the clinic: An update , 2019, Bioengineering & translational medicine.
[10] Nouri Nayerossadat,et al. Viral and nonviral delivery systems for gene delivery , 2012, Advanced biomedical research.
[11] Jin Yong Lee,et al. Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009–2016: A nationwide study , 2018, Scientific Reports.
[12] Vincent Jannin,et al. Solid lipid excipients - matrix agents for sustained drug delivery. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[13] Madhukar Pai,et al. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities , 2018, BMJ Global Health.
[14] K. Shailubhai,et al. Immunotherapy with oral administration of humanized anti‐CD3 monoclonal antibody: a novel gut‐immune system‐based therapy for metaflammation and NASH , 2018, Clinical and experimental immunology.
[15] A. Owen,et al. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. , 2019, The Journal of antimicrobial chemotherapy.
[16] Ji-Ho Park,et al. Liposomal delivery systems for intestinal lymphatic drug transport , 2016, Biomaterials Research.
[17] M. Jamei,et al. A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins , 2015, The AAPS Journal.
[18] D. Aggarwal,et al. Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.
[19] Xiaohui Chen,et al. Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes , 2016, Xenobiotica; the fate of foreign compounds in biological systems.
[20] Yin Zhang,et al. A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice , 2018, BMC Systems Biology.
[21] A. Chauhan,et al. A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man. , 2010, Journal of pharmaceutical sciences.
[22] Andrew Owen,et al. Special issue of BJP on Nanomedicine , 2014, British journal of pharmacology.
[23] Graham M. Dykes,et al. Dendrimers: a review of their appeal and applications , 2001 .
[24] D. Simberg,et al. The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses , 2019, The Journal of Pharmacology and Experimental Therapeutics.
[25] Louis A. Pagliaro,et al. Naltrexone , 2020, Reactions Weekly.
[26] C. Flexner,et al. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[27] Yahya E Choonara,et al. A prospective overview of the essential requirements in molecular modeling for nanomedicine design. , 2013, Future Medicinal Chemistry.
[28] C. V. van Halsema,et al. Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential , 2019, HIV/AIDS.
[29] Varun Jaiswal,et al. Quantitative structure–activity relationship (QSAR) studies as strategic approach in drug discovery , 2014, Medicinal Chemistry Research.
[30] A. Ostör,et al. The long road of biopharmaceutical drug development: from inception to marketing. , 2010, QJM : monthly journal of the Association of Physicians.
[31] B. Bannwarth,et al. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer? , 2017, Drugs.
[32] Amin Rostami‐Hodjegan,et al. Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence , 2017, Clinical pharmacology and therapeutics.
[33] Byung Kook Lee,et al. Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation. , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[34] C. L. Ventola,et al. The nanomedicine revolution: part 1: emerging concepts. , 2012, P & T : a peer-reviewed journal for formulary management.
[35] Robert Langer,et al. Reservoir-based drug delivery systems utilizing microtechnology. , 2012, Advanced drug delivery reviews.
[36] Theresa M Allen,et al. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.
[37] Danuta Leszczynska,et al. Chapter 10:Nano-QSAR: Advances and Challenges , 2012 .
[38] L. Citrome,et al. Aripiprazole Lauroxil , 2017, Journal of clinical psychopharmacology.
[39] Tejraj M Aminabhavi,et al. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[40] Alanod D AlQahtani,et al. Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[41] B. Ruozi,et al. Protein corona and nanoparticles: how can we investigate on? , 2017, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[42] T. Shapiro,et al. Long-acting injectable atovaquone nanomedicines for malaria prophylaxis , 2018, Nature Communications.
[43] Jim E Riviere,et al. Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. , 2009, Nano letters.
[44] Grover,et al. Quantitative structure-property relationships in pharmaceutical research - Part 2. , 2000, Pharmaceutical science & technology today.
[45] C. Flexner,et al. In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents , 2018, Clinical Pharmacokinetics.
[46] Meng Chen,et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection , 2015, Patient preference and adherence.
[47] G. De Sarro,et al. Pharmacokinetic drug-drug interaction and their implication in clinical management , 2013, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.
[48] M. Newman,et al. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs , 1999, Human & experimental toxicology.
[49] J. Qi,et al. An imaging-driven model for liposomal stability and circulation. , 2010, Molecular pharmaceutics.
[50] Baojian Wu,et al. Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112 , 2015, International journal of nanomedicine.
[51] Aravind Subramanian,et al. Perturbational profiling of nanomaterial biologic activity , 2008, Proceedings of the National Academy of Sciences.
[52] V. Torchilin. Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.
[53] Siglas de Palabras. I.L.A. , 2016 .
[54] Gina M. Prescott,et al. Long‐Acting Reversible Contraception: A Review in Special Populations , 2014, Pharmacotherapy.
[55] Raymond Laflamme,et al. A review of applications of principles of quantum physics in oncology: do quantum physics principles have any role in oncology research and applications? , 2019, Journal of Radiotherapy in Practice.
[56] M. O'Connor,et al. Identification of active signaling pathways by integrating gene expression and protein interaction data , 2018, BMC Systems Biology.
[57] Natalie von Goetz,et al. Translocation of gold nanoparticles across the lung epithelial tissue barrier: Combining in vitro and in silico methods to substitute in vivo experiments , 2015, Particle and Fibre Toxicology.
[58] A. Duschl. Chapter 12 – Nanomedicine , 2016 .
[59] C. Flexner,et al. Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling , 2019, The Journal of infectious diseases.
[60] C. Flexner,et al. Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[61] Mark R. Prausnitz,et al. Rapidly separable microneedle patch for the sustained release of a contraceptive , 2019, Nature Biomedical Engineering.
[62] M. Baliki,et al. Chronic pain: the role of learning and brain plasticity. , 2014, Restorative neurology and neuroscience.
[63] A. Mitra,et al. Long-term delivery of protein therapeutics , 2015, Expert opinion on drug delivery.
[64] Andrew Worth,et al. Applying quantitative structure-activity relationship approaches to nanotoxicology: current status and future potential. , 2013, Toxicology.
[65] D. Podzamczer,et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial , 2017, The Lancet.
[66] Tiziano Tuccinardi,et al. The History of Nanoscience and Nanotechnology: From Chemical–Physical Applications to Nanomedicine , 2019, Molecules.
[67] Ryan F. Donnelly,et al. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[68] D. Mager,et al. Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition , 2013, Pharmaceutical Research.
[69] Carlo Montemagno,et al. An Overview of Molecular Modeling for Drug Discovery with Specific Illustrative Examples of Applications , 2019, Molecules.
[70] Tomasz Puzyn,et al. Nano-quantitative structure-activity relationship modeling using easily computable and interpretable descriptors for uptake of magnetofluorescent engineered nanoparticles in pancreatic cancer cells. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.
[71] C. Yeh,et al. Macrophages as Drug Delivery Carriers for Acoustic Phase-Change Droplets. , 2018, Ultrasound in medicine & biology.
[72] Kostas Kostarelos,et al. Physiologically based pharmacokinetic modeling of nanoparticles. , 2010, ACS nano.
[73] Zuben E. Sauna,et al. Recent advances in (therapeutic protein) drug development , 2017, F1000Research.
[74] C. Free,et al. A systematic review and meta-analysis in the effectiveness of mobile phone interventions used to improve adherence to antiretroviral therapy in HIV infection , 2019, BMC Public Health.
[75] Sara Soares,et al. Nanomedicine: Principles, Properties, and Regulatory Issues , 2018, Front. Chem..
[76] Gang Bao,et al. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. , 2016, Nanomedicine.
[77] Marco Siccardi,et al. Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV , 2015, Clinical Pharmacokinetics.
[78] Ventola Cl,et al. The nanomedicine revolution: part 1: emerging concepts. , 2012, P & T : a peer-reviewed journal for formulary management.
[79] Bin Li,et al. Applications of machine learning in drug discovery and development , 2019, Nature Reviews Drug Discovery.
[80] H. Gendelman,et al. Cell-mediated drug delivery , 2011, Expert opinion on drug delivery.
[81] Ming-Hsien Tsai,et al. Computational and ultrastructural toxicology of a nanoparticle, Quantum Dot 705, in mice. , 2008, Environmental science & technology.
[82] Yanan Cui,et al. Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system , 2017, Drug development and industrial pharmacy.
[83] Y. Barenholz,et al. Annals of the New York Academy of Sciences Nanomedicines: Addressing the Scientific and Regulatory Gap , 2022 .
[84] Cristina Maderuelo,et al. Critical factors in the release of drugs from sustained release hydrophilic matrices. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[85] K. Hungerbuhler,et al. Using physiologically based pharmacokinetic (PBPK) modeling for dietary risk assessment of titanium dioxide (TiO2) nanoparticles , 2015, Nanotoxicology.
[86] T. Xia,et al. Development of structure-activity relationship for metal oxide nanoparticles. , 2013, Nanoscale.
[87] Projit Bihari Mukharji. Injection , 2017 .
[88] I. Ivanov,et al. Comparative Study of Predictive Computational Models for Nanoparticle‐Induced Cytotoxicity , 2010, Risk analysis : an official publication of the Society for Risk Analysis.
[89] Vittorio Cristini,et al. Mathematical modeling in cancer nanomedicine: a review , 2019, Biomedical Microdevices.
[90] S. Rovesti,et al. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting , 2019, Neuropsychiatric disease and treatment.
[91] M. Thew. Etonogestrel Implant—To Leave or Stay: A Case Series , 2017, Global Pediatric Health.
[92] Liang Zhao,et al. The Antibody Drug Absorption Following Subcutaneous or Intramuscular Administration and Its Mathematical Description by Coupling Physiologically Based Absorption Process with the Conventional Compartment Pharmacokinetic Model , 2013, Journal of clinical pharmacology.
[93] Julio C. Facelli,et al. A review of the applications of data mining and machine learning for the prediction of biomedical properties of nanoparticles , 2016, Comput. Methods Programs Biomed..
[94] R. Banerjee,et al. Liposomes: Applications in Medicine , 2001, Journal of biomaterials applications.
[95] Olivier Jolliet,et al. Physiologically based pharmacokinetic modeling of polyethylene glycol-coated polyacrylamide nanoparticles in rats , 2014, Nanotoxicology.
[96] D. Hazuda,et al. Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[97] T. S. Harrison,et al. Vincristine Sulfate Liposome Injection , 2013, BioDrugs.
[98] P. Cullis,et al. Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.
[99] Min Li,et al. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles , 2016, The AAPS Journal.
[100] W. Wolfgang Fleischhacker,et al. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia , 2017, Current Treatment Options in Psychiatry.
[101] A. Stein,et al. Benchmarking QSP Models Against Simple Models: A Path to Improved Comprehension and Predictive Performance , 2018, CPT: pharmacometrics & systems pharmacology.
[102] L. Sweeney,et al. Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in rats. , 2015, Regulatory toxicology and pharmacology : RTP.
[103] Can Zhang,et al. Cell-based drug delivery systems for biomedical applications , 2018, Nano Research.
[104] R. N. Brogden,et al. Dantrolene Sodium , 2020, Drugs.
[105] David Taylor,et al. Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics , 2019, Therapeutic advances in psychopharmacology.
[106] Olivier Jolliet,et al. Tissue distribution and pharmacokinetics of stable polyacrylamide nanoparticles following intravenous injection in the rat. , 2011, Toxicology and applied pharmacology.
[107] Vladimir Lobaskin,et al. Coarse-grained model of adsorption of blood plasma proteins onto nanoparticles. , 2015, The Journal of chemical physics.
[108] Hao Hu,et al. A Comprehensive Map of FDA-Approved Pharmaceutical Products , 2018, Pharmaceutics.
[109] 徐积恩. Granisetron , 1991, Reactions Weekly.
[110] Daniel Kaschek,et al. Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development , 2019, CPT: pharmacometrics & systems pharmacology.
[111] R. Upton,et al. Food, gastrointestinal pH, and models of oral drug absorption , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[112] I. Doytchinova,et al. Quantitative Structure - Pharmacokinetics Relationships Analysis of Basic Drugs: Volume of Distribution. , 2015, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[113] T. Abribat,et al. The rise and rise of drug delivery , 2005, Nature Reviews Drug Discovery.
[114] V. Krishnan,et al. Physiologically Based Pharmacokinetic Modeling of Fluorescently Labeled Block Copolymer Nanoparticles for Controlled Drug Delivery in Leukemia Therapy , 2015, CPT: pharmacometrics & systems pharmacology.
[115] P. Aubourg,et al. Hematopoietic Stem Cell Transplantation and Hematopoietic Stem Cell Gene Therapy in X‐Linked Adrenoleukodystrophy , 2009, Brain pathology.
[116] David Taylor,et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal , 2014, Therapeutic advances in psychopharmacology.
[117] V. Mishra,et al. Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems , 2018, Pharmaceutics.
[118] Andrew P. Worth,et al. QSAR modeling of nanomaterials. , 2011, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[119] Hyo-Jick Choi,et al. Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals , 2019, Pharmaceutics.
[120] P. Hoet,et al. Interactions of nanomaterials with the immune system. , 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[121] V. Stevens,et al. Predicting poor adherence to antiretroviral therapy among treatment-naïve veterans infected with human immunodeficiency virus , 2018, Medicine.
[122] H. Noteborn,et al. Drug delivery systems. , 1989, Current opinion in oncology.
[123] S. Mitragotri,et al. Nanocrystals: A perspective on translational research and clinical studies , 2018, Bioengineering & translational medicine.
[124] Jerzy Leszczynski,et al. Using nano-QSAR to predict the cytotoxicity of metal oxide nanoparticles. , 2011, Nature nanotechnology.
[125] K. Avgoustakis,et al. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content , 2012, International journal of nanomedicine.
[126] Darren Michael Moss,et al. Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling , 2014, British journal of pharmacology.
[127] A. Tropsha,et al. Quantitative nanostructure-activity relationship modeling. , 2010, ACS nano.
[128] R. Weissleder,et al. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules , 2005, Nature Biotechnology.
[129] C. Wu,et al. Delivery systems for gene therapy , 1991, Biotherapy.
[130] Vladimir Torchilin,et al. Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.
[131] S. Balu-Iyer,et al. Delivery of therapeutic proteins. , 2010, Journal of pharmaceutical sciences.
[132] S. Talegaonkar,et al. Nanocrystalization: An Emerging Technology to Enhance the Bioavailability of Poorly Soluble Drugs , 2019, Pharmaceutical nanotechnology.
[133] R. Wallerstein,et al. THE TREATMENT OF IRON-DEFICIENCY ANEMIA WITH INTRAVENOUS IRON DEXTRAN. , 1964, Blood.
[134] A. Molinari,et al. Liposomes as nanomedical devices , 2015, International journal of nanomedicine.
[135] Kit-Kay Mak,et al. Artificial intelligence in drug development: present status and future prospects. , 2019, Drug discovery today.
[136] A. Kaushik,et al. Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection , 2019, Antimicrobial Agents and Chemotherapy.
[137] A. D. V. van Staden,et al. Harnessing Macrophages for Controlled-Release Drug Delivery: Lessons From Microbes , 2019, Front. Pharmacol..
[138] Samir Mitragotri,et al. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.
[139] J. Au,et al. Target Site Delivery and Residence of Nanomedicines: Application of Quantitative Systems Pharmacology , 2019, Pharmacological Reviews.
[140] James S. Peerless,et al. Advances in Molecular Modeling of Nanoparticle-Nucleic Acid Interfaces. , 2017, Bioconjugate chemistry.
[141] I. Brosens,et al. Long-Acting Hormonal Contraception , 2015, Women's health.
[142] J Szebeni,et al. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.
[143] J. Gallant,et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. , 2017, The lancet. HIV.
[144] M. Swierczewska,et al. What is the future of PEGylated therapies? , 2015, Expert opinion on emerging drugs.
[145] H. Harashima,et al. Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[146] J. Burke,et al. Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1 , 2018, CPT: pharmacometrics & systems pharmacology.
[147] T. Koh,et al. Macrophage‐based therapeutic strategies in regenerative medicine , 2017, Advanced drug delivery reviews.
[148] Huile Gao,et al. The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior , 2014, Expert opinion on drug delivery.
[149] E. Fry. BUPRENORPHINE , 1980, The Lancet.
[150] G. Hortelano,et al. Sustained expression of coagulation factor IX by modified cord blood‐derived mesenchymal stromal cells , 2014, The journal of gene medicine.
[151] S. Wilhelm,et al. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. , 2019, Advanced drug delivery reviews.
[152] Kshirsagar. Drug delivery systems , 2000 .
[153] A. Azagew,et al. Non-adherence to anti-tuberculosis treatment, reasons and associated factors among TB patients attending at Gondar town health centers, Northwest Ethiopia , 2018, BMC Research Notes.
[154] Jerzy Leszczynski,et al. QSAR as a random event: modeling of nanoparticles uptake in PaCa2 cancer cells. , 2013, Chemosphere.